- Starting July 1, 2026, Medicare’s 18‑month “GLP‑1 Bridge” will let eligible Part D enrollees get certain GLP‑1 drugs (Wegovy, Zepbound, Foundayo) for a $50 monthly copay through Dec. 31, 2027.
- The program is focused on weight management (Medicare still can’t broadly cover weight‑loss meds); beneficiaries must meet Part D enrollment, age and BMI rules (≥27 with a qualifying condition, ≥30 with specific heart/kidney issues, or ≥35 without extra diagnosis).
- Big questions remain — CMS hasn’t disclosed cost or enrollment estimates, and observers worry about administrative snafus and potential fraud or misuse.
The news, distilled into what matters.
Get the full experience in the app — topics, comments, and audio summaries.